CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors
Yu Chen,Yingying Huang,Xuan Gao,Yi Li,Jing Lin,Lizhu Chen,Lianpeng Chang,Gang Chen,Yanfang Guan,Leong Kin Pan,Xuefeng Xia,Zengqing Guo,Jianji Pan,Yaping Xu,Xin Yi,Chuanben Chen
DOI: https://doi.org/10.3389/fimmu.2020.01620
IF: 7.3
2020-08-10
Frontiers in Immunology
Abstract:<span><i>Cyclin D1 (CCND1)</i> amplification relevant to malignant biological behavior exists in solid tumors. The prevalence and utility of <i>CCND1</i> amplification as a biomarker for the clinical response to treatment with immune checkpoint inhibitors (ICIs) are unknown. Our study is a preliminary investigation mainly focused on the predictive function of <i>CCND1</i> amplification in the tumor microenvironment (TME) in the aspect of genome and transcriptome. We examined the prevalence of <i>CCND1</i> amplification and its potential as a biomarker for the efficacy of ICI therapy for solid tumors using a local database (<i>n</i> = 6,536), The Cancer Genome Atlas (TCGA) database (<i>n</i> = 10,606), and the Memorial Sloan Kettering Cancer Center (MSKCC) database (<i>n</i> = 10,109). Comprehensive profiling was performed to determine the prevalence of <i>CCND1</i> amplification and the correlation with the prognosis and the response to ICIs. A <i>CCND1</i> amplification occurs in many cancer types and correlates with shorter overall survival and inferior outcomes with ICI therapy. Transcriptomic analysis showed various degrees of immune cell exclusion, including cytotoxic cells, T cells, CD8<sup>+</sup> T cells, dendritic cells (DCs), and B cells in the TME in a TCGA <i>CCND1</i> amplification population. The gene set enrichment analysis suggested that <i>CCND1</i> amplification correlates with multiple aggressive, immunosuppressive hallmarks including epithelial–mesenchymal transition, transforming growth factor (TGF)-β signaling, KRAS signaling, phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling, p53 pathway, and hypoxia signaling in solid tumors. These findings indicate that <i>CCND1</i> amplification may be a key point related to immunosuppression in TME and multiple malignancy hallmarks, and it hinders not only the natural host immune responses but also the efficacy of ICIs.</span>
immunology